Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 3/20 | 0.40 |
| ▸ | HTR2B | P41595 | 3/20 | 0.40 |
| ▸ | ACACB | O00763 | 1/20 | 0.34 |
| ▸ | KRAS | P01116 | 1/20 | 0.33 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.33 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24499179 | 0.84 | PTGS1 (0.35) | HTR2CACACB | |
| SCHEMBL26505578 | 0.81 | PTGS1 (0.42) | HTR2CKMT2A | |
| SCHEMBL26505576 | 0.81 | PTGS1 (0.39) | HTR2CKMT2A | |
| SCHEMBL26505564 | 0.80 | PTGS1 (0.41) | KMT2A | |
| SCHEMBL26505568 | 0.77 | FFAR4 (0.36) | SOS1 | |
| SCHEMBL22957930 | 0.77 | UTS2R (0.37) | HTR2CHTR2BACACB | |
| SCHEMBL22479882 | 0.77 | RIPK1 (0.30) | — | |
| SCHEMBL24498740 | 0.75 | PDE4D (0.37) | ACACBKRASSOS1 | |
| SCHEMBL22957925 | 0.75 | UTS2R (0.39) | HTR2CHTR2B | |
| SCHEMBL26505563 | 0.73 | RIPK1 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230139111-A1 | DIHYDRONAPHTHYRIDINONE COMPOUND, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | GENFLEET THERAPEUTICS (SHANGHAI) INC. (CN) | 2023-05-04 | — | — | US | disclosed |
| US-20230139111-A1 | DIHYDRONAPHTHYRIDINONE COMPOUND, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | GENFLEET THERAPEUTICS (SHANGHAI) INC. (CN) | 2023-05-04 | — | — | US | disclosed |
| EP-4105216-A1 | DIHYDRONAPHTHYRIDINONE COMPOUND, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | Genfleet Therapeutics (Shanghai) Inc. (CN) | 2022-12-21 | — | — | EP | disclosed |
| EP-3943488-A1 | SUBSTITUTED HETEROCYCLIC AMIDE COMPOUND AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | Genfleet Therapeutics (Shanghai) Inc. (CN) | 2022-01-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230139111-A1 | DIHYDRONAPHTHYRIDINONE COMPOUND, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | RIPK1, RIPK4, RIPK3 | HTR2C 3826/4885HTR2B 3303/4885ACACB 4679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.